Kenvue Inc. $KVUE Shares Acquired by Alberta Investment Management Corp

Alberta Investment Management Corp grew its position in shares of Kenvue Inc. (NYSE:KVUE) by 23.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,106,716 shares of the company’s stock after purchasing an additional 213,000 shares during the quarter. Alberta Investment Management Corp owned approximately 0.06% of Kenvue worth $17,962,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in Kenvue by 1.8% during the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after purchasing an additional 4,101,880 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Kenvue by 27.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 310,686 shares of the company’s stock valued at $5,042,000 after buying an additional 66,192 shares during the period. Aviva PLC grew its position in shares of Kenvue by 6.8% during the 2nd quarter. Aviva PLC now owns 1,432,477 shares of the company’s stock valued at $29,982,000 after buying an additional 91,744 shares during the last quarter. Bessemer Group Inc. grew its position in shares of Kenvue by 40.6% during the 2nd quarter. Bessemer Group Inc. now owns 3,319,933 shares of the company’s stock valued at $69,487,000 after buying an additional 958,757 shares during the last quarter. Finally, Ethic Inc. raised its stake in Kenvue by 7.8% during the second quarter. Ethic Inc. now owns 237,758 shares of the company’s stock worth $4,964,000 after acquiring an additional 17,189 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE stock opened at $18.87 on Thursday. The company has a 50-day simple moving average of $17.48 and a 200 day simple moving average of $17.66. The company has a market capitalization of $36.15 billion, a P/E ratio of 24.51 and a beta of 0.59. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. The company had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.86%. Kenvue’s revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.26 EPS. Sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be given a dividend of $0.2075 per share. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Insider Activity at Kenvue

In other news, Director Jeffrey C. Smith bought 3,200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was acquired at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the purchase, the director directly owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. This represents a 13.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.68% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on KVUE. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Citigroup raised their price target on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft set a $18.00 price objective on Kenvue in a research note on Friday, October 24th. Evercore set a $18.00 target price on Kenvue in a research note on Tuesday, October 28th. Finally, Johnson Rice restated a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Four investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus price target of $20.08.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.